文献速递白血病

ENO1通过SCD1介导的脂质代谢重编程促进急性髓系白血病进展

ENO1 promotes acute myeloid leukemia progression through SCD1-mediated lipid metabolism reprogramming.
PubMed 文献 · Blood Adv · 2026-01-01

本研究探讨ENO1高表达与AML肿瘤加速进展及不良预后之间的关联。转录组和代谢组分析表明ENO1通过调控SCD1表达直接调节脂质代谢,并作为DNA结合蛋白与SCD1启动子区相互作用增强SCD1转录。SCD1抑制剂SSI-4可增强柔红霉素对高ENO1表达AML细胞的化疗敏感性。

要点

  • ENO1高表达与AML肿瘤加速进展及不良预后相关
  • ENO1作为DNA结合蛋白结合SCD1启动子增强其转录
  • SSI-4抑制SCD1可增强柔红霉素对高ENO1表达AML的敏感性

核心结论

  • ENO1通过促进SCD1转录驱动脂质重编程和铁死亡抵抗,从而促进AML进展。
  • 抑制SCD1联合柔红霉素对高ENO1表达AML患者具有治疗潜力。

研究设计与样本

  • 实验研究,采用转录组和代谢组分析探讨ENO1与SCD1及脂质代谢的关联。

主要发现

  • ENO1高表达与AML肿瘤加速进展和不良预后相关。
  • ENO1直接调控SCD1表达,作为DNA结合蛋白与SCD1启动子区相互作用增强SCD1转录。
  • SCD1转录增强导致单不饱和脂肪酸合成增加,从而增加对脂质过氧化和铁死亡的抵抗。
  • SCD1抑制剂SSI-4可增强柔红霉素对高ENO1表达AML细胞的化疗敏感性。

临床怎么用

  • 对高ENO1表达的AML患者,可考虑SCD1抑制联合柔红霉素的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

α-Enolase (ENO1) is a potential therapeutic target in acute myeloid leukemia (AML), owing to its elevated expression in AML cells. In this study, we investigated the association between high ENO1 expression, accelerated tumor progression, and poor AML prognosis. Transcriptomic and metabolomic analyses indicated that ENO1 directly modulates lipid metabolism via regulating stearoyl-coenzyme A desaturase 1 (SCD1) expression. We further demonstrated that ENO1 functions as a DNA-binding protein, interacting with the SCD1 promoter region to enhance SCD1 transcription. This results in increased synthesis of monounsaturated fatty acids, leading to increased resistance to lipid peroxidation and ferroptosis. Based on these results, we found that SSI-4, an SCD1 inhibitor, could enhance chemosensitivity of daunorubicin (DNR), which can induce ferroptosis in tumor cells, effectively reducing the resistance to ferroptosis in AML cells exhibiting high ENO1 expression. Overall, our study elucidates the mechanism of ENO1 that promotes SCD1 transcription, driving lipid reprogramming and ferroptosis resistance within AML. In addition, it highlights the therapeutic potential of combining SCD1 inhibition with DNR for patients with AML with elevated ENO1 expression levels.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wu Y, Gao L, Fang F, et al. ENO1 promotes acute myeloid leukemia progression through SCD1-mediated lipid metabolism reprogramming. Blood Adv. 2026. PMID: 42048629. doi:10.1182/bloodadvances.2025017973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。